Finance

Bayer CEO says Roundup settlement is important addition to Supreme Court case

Published by Global Banking & Finance Review

Posted on February 17, 2026

1 min read

· Last updated: February 17, 2026

Add as preferred source on Google
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Global Banking & Finance Awards 2026 — Call for Entries

BERLIN, Feb 17 (Reuters) - Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court

Bayer's Roundup Settlement Key to Supreme Court Case Strategy

Bayer's Legal Strategy and Settlement

BERLIN, Feb 17 (Reuters) - Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anderson said on Tuesday.

Importance of the Settlement

"We are entering into the settlement because it is an important addition to the case before the Supreme Court, thereby minimising the legal risks as comprehensively as possible," he said.

Minimizing Legal Risks

"Both elements are necessary independently of each other and reinforce each other," he added.

(Writing by Friederike HeineEditing by David Goodman)

Key Takeaways

  • Bayer's settlement aims to resolve Roundup claims.
  • The settlement is crucial for the Supreme Court case.
  • Bayer seeks to minimize legal risks comprehensively.
  • CEO Bill Anderson emphasizes dual strategy importance.
  • The settlement and court case strategies are interlinked.

Frequently Asked Questions

What is non-Hodgkin lymphoma?
Non-Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, which is part of the body's immune system. It can vary in severity and is often treated with chemotherapy or radiation.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category